With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...
A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage ...
Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data ...
Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.
BofA Securities, TD Cowen, Stifel, Cantor and William Blair are acting as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital, BTIG and Jones are acting as co-managers for ...
Srinagar- Head and neck cancers are on the rise in Kashmir, with Srinagar and Anantnag districts showing the highest number ...
Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to 142 patients to date in Company- and investigator-sponsored ...
The median DOR in NRG1+ NSCLC was 7.4 months. b writes, “Investor focus remains on petosemtamab, with the next key catalyst ...